CyberKnife Ultra-hypofractionated SBRT for Localized PROStatE cancEr

This is a prospective observational study. The study will proceed with the enrollment of 60 patients in 2 years. he aim of the present study is to evaluate effectiveness of ultra-hypofractionated (UH) CyberKnife Stereotactic Body Radiation Therapy treatment on the whole prostate gland plus Simultaneous integrated boost (SIB) to the dominant intraprostatic lesions (DIL(s) in intermediate-unfavourable to high-risk Prostate Cancer (PCa) patients.

Trial Details

NCT ID
NCT06331013
Phase
NA
Sponsor
European Institute of Oncology
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • CyberKnife ultra-hypofractionated SBRT
Locations (sample)
  • Milan, Italy|45.46427,9.18951

Key Eligibility Criteria

  • Age \> 18 and \< 80 years
  • Histologically confirmed adenocarcinoma of the prostate
  • Low, Intermediate and high-risk category according to NCCN version 02.2021
  • Clinically node negative and no distant metastasis

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →